Abstract
Protein ingested with breast milk provides indispensable amino acids which are necessary for new protein synthesis for growth and replacement of losses via urine, feces, and the skin. Protein gain in the body of an infant is highest during the first months when protein concentrations in breast milk are higher than during later stages of lactation. Low-birth-weight infants have higher protein needs than term infants and need protein supplements during feeding with breastmilk. Based on our better understanding of protein evolution in breastmilk during the stages of lactation, new infant formulas with lower protein concentration but better protein quality have been created, successfully tested, and are now available in many countries. Besides providing indispensable amino acids, bioactive protein in breast milk can be broadly classified into 4 major functions, that is, providing protection from microbial insults and immune protection, aiding in digestive functions, gut development, and being carriers for other nutrients. Individual proteins and their proposed bioactivities are summarized in this paper in brief. Indeed, some proteins like lactoferrin and sIgA have been extensively studied for their biological functions, whereas others may require more data in support to further validate their proposed functions.
Journal Section:
Human Milk: Lessons from Recent Research
References
1.
Haschke F, et al: Feeding patterns during the first 2 years and health outcome. Ann Nutr Metab 2013;62(suppl 3):16-25.
2.
Global Burden of Disease Study 2013 Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800.
3.
Fomon SJ: Requirements and recommended dietary intakes of protein during infancy. Pediatr Res 1991;30:391-395.
4.
Heinig MJ, et al: Energy and protein intakes of breast-fed and formula-fed infants during the first year of life and their association with growth velocity: the DARLING Study. Am J Clin Nutr 1993;58:152-161.
5.
Lönnerdal B, Erdmann P, Thakkar SK, Sauser J, Destaillats F: Longitudinal evolution of true protein, amino acids and bioactive proteins in breast milk: a developmental perspective. J Nutr Biochem 2016;41:1-11.
6.
Donovan SM, et al: Partition of nitrogen intake and excretion in low-birth-weight infants. Am J Dis Child 1989;143:1485-1491.
7.
Fomon SJ, et al: Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982;35(suppl):1169-1175.
8.
Zhang Z, et al: Amino acid profiles in term and preterm human milk through lactation: a systematic review. Nutrients 2013;5:4800-4821.
9.
Ziegler EE, et al: Body composition of the reference fetus. Growth 1976;40:329-341.
10.
Haschke F, Grathwohl D, Haiden N: Metabolic programming: effects of early nutrition on growth, metabolism and body composition. Nestle Nutr Inst Workshop Ser 2016;86:87-95.
11.
Dewey KG, et al: Breast-fed infants are leaner than formula-fed infants at 1 y of age: the DARLING study. Am J Clin Nutr 1993;57:140-145.
12.
Weber M, et al: Lower protein content in infant formula reduces BMI and obesity risk at school age: follow-up of a randomized trial. Am J Clin Nutr 2014;99:1041-1051.
13.
Axelsson IE, Ivarsson SA, Raiha NC: Protein intake in early infancy: effects on plasma amino acid concentrations, insulin metabolism, and growth. Pediatr Res 1989;26:614-617.
14.
Socha P, et al: Milk protein intake, the metabolic-endocrine response, and growth in infancy: data from a randomized clinical trial. Am J Clin Nutr 2011;94(suppl):1776S-1784S.
15.
Alexander DD, et al: Growth of infants consuming whey-predominant term infant formulas with a protein content of 1.8 g/100 kcal: a multicenter pooled analysis of individual participant data. Am J Clin Nutr 2016;104:1083-1092.
16.
Raiha NC, et al: Whey predominant, whey modified infant formula with protein/energy ratio of 1.8 g/100 kcal: adequate and safe for term infants from birth to four months. J Pediatr Gastroenterol Nutr 2002;35:275-281.
17.
Haschke F, et al: Postnatal high protein intake can contribute to accelerated weight gain of infants and increased obesity risk. Nestle Nutr Inst Workshop Ser 2016;85:101-109.
18.
WHO: WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age, Methods and Development. Geneva, WHO, 2016.
19.
Inostroza J, et al: Low-protein formula slows weight gain in infants of overweight mothers. J Pediatr Gastroenterol Nutr 2014;59:70-77.
20.
Ziegler EE, et al: Adequacy of infant formula with protein content of 1.6 g/100 kcal for infants between 3 and 12 months. J Pediatr Gastroenterol Nutr 2015;61:596-603.
21.
Dewey KG, Heinig MJ, Nommsen-Rivers LA: Differences in morbidity between breast-fed and formula-fed infants. J Pediatr 1995;126:696-702.
22.
Isolauri E: Development of healthy gut microbiota early in life. J Paediatr Child Health 2012;48(suppl 3):1-6.
23.
Blanc B, Bujard E, Mauron J: The amino acid composition of human and bovine lactotransferrins. Experientia 1963;19:299-301.
24.
Siqueiros-Cendon T, et al: Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin 2014;35:557-566.
25.
Lonnerdal B, Iyer S: Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995;15:93-110.
26.
Rai D, et al: Longitudinal changes in lactoferrin concentrations in human milk: a global systematic review. Crit Rev Food Sci Nutr 2014;54:1539-1547.
27.
Lonnerdal B: Bioactive proteins in breast milk. J Paediatr Child Health 2013;49(suppl 1):1-7.
28.
Actor JK, Hwang SA, Kruzel ML: Lactoferrin as a natural immune modulator. Curr Pharm Des 2009;15:1956-1973.
29.
Tomita M, et al: Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 1991;74:4137-4142.
30.
Edde L, et al: Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 2001;281:G1140-G1150.
31.
Bruni N, et al: Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules 2016;21:E752.
32.
Brouwer CP, Rahman M, Welling MM: Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 2011;32:1953-1963.
33.
Goldman AS, et al: Immunologic factors in human milk during the first year of lactation. J Pediatr 1982;100:563-567.
34.
Lycke N, et al: Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol 1999;163:913-919.
35.
Silvey KJ, et al: Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches. J Virol 2001;75:10870-10879.
36.
Forbes SJ, et al: Transient suppression of Shigella flexneri type 3 secretion by a protective O-antigen-specific monoclonal IgA. MBio 2011;2:e00042-11.
37.
Stokes CR, Soothill JF, Turner MW: Immune exclusion is a function of IgA. Nature 1975;255:745-746.
38.
Ashkar S, et al: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864.
39.
Schack L, et al: Considerable variation in the concentration of osteopontin in human milk, bovine milk, and infant formulas. J Dairy Sci 2009;92:5378-5385.
40.
Maeno Y, et al: Effect of osteopontin on diarrhea duration and innate immunity in suckling mice infected with a murine rotavirus. Viral Immunol 2009;22:139-144.
41.
Pabst HF, et al: Differential modulation of the immune response by breast- or formula-feeding of infants. Acta Paediatr 1997;86:1291-1297.
42.
Azuma N, Maeta A, Fukuchi K, Kanno C: A rapid method for purifying osteopontin from bovine milk and interaction between osteopontin and other milk proteins. Int Dairy J 2006;16:370-378.
43.
Lonnerdal B, et al: Growth, nutrition, and cytokine response of breast-fed infants and infants fed formula with added bovine osteopontin. J Pediatr Gastroenterol Nutr 2016;62:650-657.
44.
Soder O: Isolation of interleukin-1 from human milk. Int Arch Allergy Appl Immunol 1987;83:19-23.
45.
Hooton JW, et al: Human colostrum contains an activity that inhibits the production of IL-2. Clin Exp Immunol 1991;86:520-524.
46.
Sarfati M, et al: Presence of IgE suppressor factors in human colostrum. Eur J Immunol 1986;16:1005-1008.
47.
Munoz C, et al: Interleukin-1 beta in human colostrum. Res Immunol 1990;141:505-513.
48.
Rudloff HE, et al: Tumor necrosis factor-alpha in human milk. Pediatr Res 1992;31:29-33.
49.
Saito S, et al: Detection of IL-6 in human milk and its involvement in IgA production. J Reprod Immunol 1991;20:267-276.
50.
Garofalo R, et al: Interleukin-10 in human milk. Pediatr Res 1995;37:444-449.
51.
Eglinton BA, Roberton DM, Cummins AG: Phenotype of T cells, their soluble receptor levels, and cytokine profile of human breast milk. Immunol Cell Biol 1994;72:306-313.
52.
Grosvenor CE, Picciano MF, Baumrucker CR: Hormones and growth factors in milk. Endocr Rev 1993;14:710-728.
53.
Lonnerdal B: Human milk proteins: key components for the biological activity of human milk. Adv Exp Med Biol 2004;554:11-25.
54.
Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003;77:1537S-1543S.
55.
Golinelli LP, Del Aguila EM, Flosi Paschoalin VM, Silva JT, Conte-Junior CA: Functional aspect of colostrum and whey proteins in human milk. J Hum Nutr Food Sci 2014;2:1035.
56.
Cooper CA, Maga EA, Murray JD: Production of human lactoferrin and lysozyme in the milk of transgenic dairy animals: past, present, and future. Transgenic Res 2015;24:605-614.
57.
Lee-Huang S, et al: Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci USA 1999;96:2678-2681.
58.
Cuilliere ML, et al: Changes in the kappa-casein and beta-casein concentrations in human milk during lactation. J Clin Lab Anal 1999;13:213-218.
59.
Stromqvist M, et al: Human milk kappa-casein and inhibition of Helicobacter pylori adhesion to human gastric mucosa. J Pediatr Gastroenterol Nutr 1995;21:288-296.
60.
Shin K, Tomita M, Lonnerdal B: Identification of lactoperoxidase in mature human milk. J Nutr Biochem 2000;11:94-102.
61.
Steele WF, Morrison M: Antistreptococcal activity of lactoperoxidase. J Bacteriol 1969;97:635-639.
62.
Bjorck L, et al: Antibacterial activity of the lactoperoxidase system in milk against pseudomonads and other gram-negative bacteria. Appl Microbiol 1975;30:199-204.
63.
Aoki,Y, Kobayashi K, Kajii T: Enzyme-linked immunoassay of haptocorrin: analysis of milk and granulocytes. Biochem Med Metab Biol 1992;47:189-194.
64.
Adkins Y, Lonnerdal B: Potential host-defense role of a human milk vitamin B-12-binding protein, haptocorrin, in the gastrointestinal tract of breastfed infants, as assessed with porcine haptocorrin in vitro. Am J Clin Nutr 2003;77:1234-1240.
65.
Jensen HR, et al: Effect of the vitamin B12-binding protein haptocorrin present in human milk on a panel of commensal and pathogenic bacteria. BMC Res Notes 2011;4:208.
66.
Lonnerdal B, Lien EL: Nutritional and physiologic significance of alpha-lactalbumin in infants. Nutr Rev 2003;61:295-305.
67.
Permyakov EA, Berliner LJ: Alpha-lactalbumin: structure and function. FEBS Lett 2000;473:269-274.
68.
Pellegrini A, et al: Isolation and identification of three bactericidal domains in the bovine alpha-lactalbumin molecule. Biochim Biophys Acta 1999;1426:439-448.
69.
Wada Y, Lonnerdal B: Bioactive peptides derived from human milk proteins - mechanisms of action. J Nutr Biochem 2014;25:503-514.
70.
Hakansson A, et al: A folding variant of alpha-lactalbumin with bactericidal activity against Streptococcus pneumoniae. Mol Microbiol 2000;35:589-600.
71.
Lien EL: Infant formulas with increased concentrations of alpha-lactalbumin. Am J Clin Nutr 2003;77:1555S-1558S.
72.
Blackberg L, et al: The bile salt-stimulated lipase in human milk is an evolutionary newcomer derived from a non-milk protein. FEBS Lett 1980;112:51-54.
73.
Freudenberg E: Lipase of human milk; studies on its enzymological and nutritional significance. Bibl Paediatr 1953;9:1-68.
74.
Blackberg L, Hernell O: The bile-salt-stimulated lipase in human milk. Purification and characterization. Eur J Biochem 1981;116:221-225.
75.
Blackberg L, et al: Bile salt-stimulated lipase in human milk and carboxyl ester hydrolase in pancreatic juice: are they identical enzymes? FEBS Lett 1981;136:284-288.
76.
Hernell O, Blackberg L: Digestion of human milk lipids: physiologic significance of sn-2 monoacylglycerol hydrolysis by bile salt-stimulated lipase. Pediatr Res 1982;16:882-885.
77.
Lindquist S, Hernell O: Lipid digestion and absorption in early life: an update. Curr Opin Clin Nutr Metab Care 2010;13:314-320.
78.
Fredrikzon B, et al: Bile salt-stimulated lipase in human milk: evidence of activity in vivo and of a role in the digestion of milk retinol esters. Pediatr Res 1978;12:1048-1052.
79.
Andersson Y, et al: Pasteurization of mother's own milk reduces fat absorption and growth in preterm infants. Acta Paediatr 2007;96:1445-1449.
80.
Casper C, et al: Recombinant bile salt-stimulated lipase in preterm infant feeding: a randomized phase 3 study. PLoS One 2016;11:e0156071.
81.
Heitlinger LA, et al: Mammary amylase: a possible alternate pathway of carbohydrate digestion in infancy. Pediatr Res 1983;17:15-18.
82.
Lindberg T, Skude G: Amylase in human milk. Pediatrics 1982;70:235-238.
83.
Dewit O, Dibba B, Prentice A: Breast-milk amylase activity in English and Gambian mothers: effects of prolonged lactation, maternal parity, and individual variations. Pediatr Res 1990;28:502-506.
84.
Hegardt P, et al: Amylase in human milk from mothers of preterm and term infants. J Pediatr Gastroenterol Nutr 1984;3:563-566.
85.
McGilligan KM, Thomas DW, Eckhert CD: Alpha-1-antitrypsin concentration in human milk. Pediatr Res 1987;22:268-270.
86.
Davidson LA, Lonnerdal B: Fecal alpha 1-antitrypsin in breast-fed infants is derived from human milk and is not indicative of enteric protein loss. Acta Paediatr Scand 1990;79:137-141.
87.
Wright G, et al: High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (NY) 1991;9:830-834.
88.
Carver A, et al: Expression of human alpha 1 antitrypsin in transgenic sheep. Cytotechnology 1992;9:77-84.
89.
Donovan SM, Odle J: Growth factors in milk as mediators of infant development. Annu Rev Nutr 1994;14:147-167.
90.
Playford RJ, Macdonald CE, Johnson WS: Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 2000;72:5-14.
91.
Dvorak B, et al: Increased epidermal growth factor levels in human milk of mothers with extremely premature infants. Pediatr Res 2003;54:15-19.
92.
Buccigrossi V, et al: Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007;61:410-414.
93.
Reznikov EA, et al: Dietary bovine lactoferrin increases intestinal cell proliferation in neonatal piglets. J Nutr 2014;144:1401-1408.
94.
Hernell O, Lonnerdal B: Iron status of infants fed low-iron formula: no effect of added bovine lactoferrin or nucleotides. Am J Clin Nutr 2002;76:858-864.
95.
Saarinen UM, Siimes MA, Dallman PR: Iron absorption in infants: high bioavailability of breast milk iron as indicated by the extrinsic tag method of iron absorption and by the concentration of serum ferritin. J Pediatr 1977;91:36-39.
96.
Kawakami H, Lonnerdal B: Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J Physiol 1991;261:G841-G846.
97.
Suzuki YA, et al: Expression, characterization, and biologic activity of recombinant human lactoferrin in rice. J Pediatr Gastroenterol Nutr 2003;36:190-199.
98.
Burger RL, Allen RH: Characterization of vitamin B12-binding proteins isolated from human milk and saliva by affinity chromatography. J Biol Chem 1974;249:7220-7227.
99.
Seetharam B, Alpers DH: Absorption and transport of cobalamin (vitamin B12). Annu Rev Nutr 1982;2:343-369.
100.
Adkins Y, Lonnerdal B: Mechanisms of vitamin B(12) absorption in breast-fed infants. J Pediatr Gastroenterol Nutr 2002;35:192-198.
101.
Nygren-Babol L, Jagerstad M: Folate-binding protein in milk: a review of biochemistry, physiology, and analytical methods. Crit Rev Food Sci Nutr 2012;52:410-425.
102.
Ford JE, Salter DN, Scott KJ: A folate-protein complex in cow's milk. Proc Nutr Soc 1969;28:39A-40A.
103.
Ford JE: Observations on the possible nutritional significance of vitamin-binding proteins in milk. Proc Nutr Soc 1974;33:15A.
104.
Ford JE: Some observations on the possible nutritional significance of vitamin B12-and folate-binding proteins in milk. Br J Nutr 1974;31:243-257.
105.
Wigertz K, Svensson UK, Jagerstad M: Folate and folate-binding protein content in dairy products. J Dairy Res 1997;64:239-252.
106.
Indyk HE, Filonzi EL, Gapper LW: Determination of minor proteins of bovine milk and colostrum by optical biosensor analysis. J AOAC Int 2006;89:898-902.
107.
Kelleher SL, et al: Glycomacropeptide and alpha-lactalbumin supplementation of infant formula affects growth and nutritional status in infant rhesus monkeys. Am J Clin Nutr 2003;77:1261-1268.
108.
Szymlek-Gay EA, et al: α-Lactalbumin and casein-glycomacropeptide do not affect iron absorption from formula in healthy term infants. J Nutr 2012;142:1226-1231.
109.
Kunz C, Lonnerdal B: Re-evaluation of the whey protein/casein ratio of human milk. Acta Paediatr 1992;81:107-112.
110.
Kunz C, Lonnerdal B: Human-milk proteins: analysis of casein and casein subunits by anion-exchange chromatography, gel electrophoresis, and specific staining methods. Am J Clin Nutr 1990;51:37-46.
111.
Sato R, Noguchi T, Naito H: Casein phosphopeptide (CPP) enhances calcium absorption from the ligated segment of rat small intestine. J Nutr Sci Vitaminol (Tokyo) 1986;32:67-76.
112.
Ferraretto A, et al: Casein phosphopeptides influence calcium uptake by cultured human intestinal HT-29 tumor cells. J Nutr 2001;131:1655-1661.
113.
Liu KY, et al: Natural killer cell populations and cytotoxic activity in pigs fed mother's milk, formula, or formula supplemented with bovine lactoferrin. Pediatr Res 2013;74:402-407.
114.
Hurley WL, Theil PK: Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011;3:442-474.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.
